MaaT Pharma Eyes FDA Meeting, Advances Cancer Drug MaaT034 for Solid Tumors
MaaT Pharma has scheduled a Pre-IND CMC-focused meeting with the FDA in October 2026 for its MaaT034 drug candidate and plans to advance it into clinical development for solid tumors. A First-in-Human study, subject to funding and regulatory clearance, could be initiated in late 2027.